International Post Market Surveillance Study of Intracranial Aneurysms Treated With an Endovascular Approach

Inclusion Criteria (Evolve EU and Evolve FR): * Subject has an intracranial aneurysm that can be treated with one of the proposed devices * Subject age is ≥ 18 years * Subject or subject's legally authorized representative (LAR) has signed written informed consent * Subject is willing to comply with scheduled visits and examinations per institutional standard of care Exclusion Criteria for (Evolve EU and Evolve FR): * Subject is pregnant or plans to become pregnant her study participation\*. * Subject is currently enrolled in or plans to be enrolled in a concurrent drug or device study. * Subject has a condition which will not allow him/her to comply with his/her post-procedure follow up per the institutional standard of care (medical condition, subject living abroad and unable to return for follow-up, e.g.). * Subject has a non-target aneurysm treated within 30 days prior to study enrollment. * Subject has a planned treatment of a non-target aneurysm in the same vascular territory during participation in the study. * Subject target aneurysm is a ruptured intracranial aneurysm (unless ruptured at least 21 days prior the day of the index procedure) * Subject has a target aneurysm other than saccular or fusiform intracranial aneurysms; e.g.: vertebrobasilar dolichoectasia (VBD) * The parent vessel size does not fall within the indicated range defined by IFU * Antiplatelet and/or anticoagulation therapy (e.g., aspirin and clopidogrel) is contraindicated for the subject * Subject has not received dual anti-platelet agents prior to the procedure or equivalent in accordance with standard medical practice * Subject has an active bacterial or viral infection * The angiography demonstrates the anatomy is not appropriate for endovascular treatment, due to conditions such as: * Severe intracranial vessel tortuosity or stenosis; and/or * Intracranial vasospasm not responsive to medical therapy Additional Key Exclusion Criteria (Evolve EU only): * Subject has a non-target aneurysm treated within 30 days prior to study enrollment * Subject has a planned treatment of a non-target aneurysm in the same vascular territory during participation in the study * Subject has a modified Rankin Score (mRS) ≥3 at pre-procedure examination * Subject has undergone previous stent assisted coiling or flow diverter treatment of a parent artery aneurysm near the location of the target aneurysm